Skip to main content

Table 3 Distribution of the R497K and (CA)n genotypes according to prognostic variables

From: Epidermal growth factor receptor gene polymorphisms are associated with prognostic features of breast cancer

Prognostic variables   R497K   (CA)n
Arg/Arg Arg/Lys Lys/Lys   Short/short Short/long Long/long  
Total n = 308 n = 176 n = 21 Total n = 108 n = 230 n = 139  
  n % % % P n % % % P
Age           
  > 35 years-old 493 61.7 34.1 4.3 0.06 466 22.7 48.5 28.8 0.48
  ≤ 35 years-old 112 33.3 66.7 0.0   11 18.2 36.4 45.5  
Familial history           
 No 400 60.0 36.0 4.0 0.99 376 21,5 49,7 28,7 0.38
 Yes 56 60.7 35.7 3.6   53 26,4 39,6 34.0  
Histological type           
in situ 35 62.9 34.3 2.9 0.91 33 15.2 48.5 36.4 0.44
 Invasive 459 61.0 34.6 4.4   434 23.3 48.6 28.1  
Tumor grade           
 Grade 1 60 56.7 40.0 3.3 0.64 58 25.9 46.6 27.6 0.74
 Grade 2 or 3 413 61.3 34.1 4.6   389 21.3 48.8 29.8  
Tumor size           
 pT ≤ 2 cm 224 59.4 36.6 4.0 0.65 214 22.9 45.3 31.8 0.24
 pT > 2 cm 233 62.7 32.6 4.7   218 23.4 51.8 29.8  
Lymph node status           
 pN0 or pN1 429 58.0 37.3 4.7 0.005 405 22.7 47.2 30.1 0.47
 pN2 or pN3 76 77.6 21.1 1.3   72 22.2 54.2 23.6  
ER status           
 Negative 76 68.4 27.6 3.9 0.38 72 26.4 51.4 22.2 0.29
 Positive 411 60.1 35.5 4.4   387 21.2 47.8 31.0  
PR status           
 Negative 133 63.2 32.3 4.5 0.87 128 28.1 50.0 21.9 0.031
 Positive 353 60.9 34.8 4.2   330 19.4 47.9 32.7  
HER2 status           
 Negative 376 59.3 35.6 5.1 0.13 356 21.9 50.0 28.1 0.30
 Positive 72 65.3 34.7 0.0   67 20.9 41.8 37.3  
Biological classification           
 Luminal A 291 58.8 36.4 4.8 0.68 275 20.0 49.8 30.2 0.35
 Luminal B 88 60.2 36.4 3.4 83 21.7 43.4 34.9
 HER2 like 26 73.1 26.9 0.0 24 37.5 41.7 20.8
 Triple negative 44 63.6 29.5 6.8   42 23.8 54.8 21.4  
  1. Data are expressed as the number of patients and respective percentages in each category. (CA)n Short: n ≤ 16; (CA)n Long: n > 16. Abbreviations: ER Estrogen Receptor, PR Progesterone Receptor, HEr2 Human Epidermal groth factor Receptor 2. Statistically significant differences are presented in bold characters.